Search results for "OSiS"

showing 10 items of 15931 documents

Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors.

2018

Due to an increased understanding of molecular biology and the genomics of cancer, new and potent agents have been approved by the Food and Drug Administration (FDA) to fight this disease. However, all of these drugs cause severe side effects and resistance inevitably develops, re-activating tumor growth and dissemination. For this reason, patients turn to natural compounds as alternative or complementary treatment options, since it has been found that natural plant products may block, inhibit, or reverse cancer development. The present review focusses on the role of the natural compound sulforaphane (SFN) as an anti-tumor agent in urologic cancer. SFN is a natural compound found in crucife…

0301 basic medicineCancer ResearchUrologic NeoplasmsApoptosisDisease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoIsothiocyanatesCell Line TumorHDAC inhibitorMedicineAnticarcinogenic AgentsHumansEpigeneticsMode of actionBiological ProductsMolecular Structurebusiness.industryCruciferous vegetablesCancermedicine.diseaseHistone Deacetylase Inhibitors030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisSulfoxidesBrassicaceaeCancer researchbusinessSulforaphaneCancer letters
researchProduct

The importance of transmembrane domain interactions in the viral control of apoptosis

2021

Viral control of apoptosis occurs through the expression of viral encoded anti-apoptotic B-cell lymphoma 2 (BCL2) analogs. These proteins are thought to restrain apoptosis by interacting with cellular BCL2 family members. We identified that protein-protein interactions between cellular and viral BCL2 transmembrane domains are crucial for the viral protein’s function.

0301 basic medicineCancer ResearchViral proteinChemistryvirusesmedicine.diseasemedicine.disease_cause030112 virologyTransmembrane proteinLymphomaCell biology03 medical and health sciencesTransmembrane domain030104 developmental biologyimmune system diseasesApoptosishemic and lymphatic diseasesAuthor’s ViewsmedicineMolecular Medicinebiological phenomena cell phenomena and immunityneoplasmsFunction (biology)Molecular & Cellular Oncology
researchProduct

Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide

2018

Rationale: The activity of the transcription factor, hypoxia-inducible factor (HIF)-1?, is a common driver of a number of the pathways involved in the aggressiveness of glioblastomas (GBMs), and it has been suggested that the reduction in this activity observed, soon after the administration of temozolomide (TMZ), can be a biomarker of an early response in GBM models. As HIF-1? is a tightly regulated protein, studying the processes involved in its downregulation could shed new light on the mechanisms underlying GBM sensitivity or resistance to TMZ. Methods: The effect of HIF-1? silencing on cell responsiveness to TMZ was assessed in four genetically different human GBM cell lines by evaluat…

0301 basic medicineCancer Researchapoptosis; chaperone-mediated autophagy activity; hypoxia-inducible factor-1? silencing; temozolomide responsiveness; theranostic biomarkerBiologylcsh:RC254-28203 medical and health scienceshypoxia-inducible factor-1α silencing0302 clinical medicineGliomamedicineGene silencingViability assayTranscription factorOriginal Researchchaperone-mediated autophagy activityTemozolomideAutophagyapoptosismedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenstheranostic biomarker030104 developmental biologyHypoxia-inducible factorsOncologyApoptosis030220 oncology & carcinogenesisCancer researchtemozolomide responsivenessmedicine.drugFrontiers in Oncology
researchProduct

Targeting Immune Modulators in Glioma While Avoiding Autoimmune Conditions

2021

Simple Summary Glioblastoma multiforme is a futile disease usually leading to the patient’s death within one year post-diagnosis; therefore, novel treatment options are desperately needed. In this regard, activation of the inert immune system has moved into focus in recent years. Malignant brain tumors, as well as autoimmune diseases, elicit aberrant immune responses. In this way, glioma escapes the host’s immune system and, thus, activation of the immune response in order to reduce tumor tolerance can serve as an alternative treatment option. Immune checkpoint modulators in combination with traditional therapies have gained attention in both glioma and autoimmune diseases. In this review, …

0301 basic medicineCancer Researchautoimmune disease ; immune checkpoints ; immunotherapy ; clinical trials ; Gliom ; gliomamedicine.medical_treatmentautoimmune diseaseContext (language use)Review03 medical and health sciences0302 clinical medicineImmune systemgliomaGliomamedicineRC254-282Autoimmune diseaseclinical trialsTumor microenvironmentbusiness.industryMultiple sclerosisNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunosuppressionImmunotherapybiochemical phenomena metabolism and nutritionimmune checkpointsmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchimmunotherapybusinessCancers
researchProduct

Molecular Basis of Mismatch Repair Protein Deficiency in Tumors from Lynch Suspected Cases with Negative Germline Test Results

2020

Some 10&ndash

0301 basic medicineCancer Researchcongenital hereditary and neonatal diseases and abnormalitiesCARCINOMADNA mismatch repair3122 Cancerscolorectal cancersuolistosyövätBiologyGene mutationMLH1DIAGNOSISlcsh:RC254-282Article03 medical and health sciencesdeep sequencing0302 clinical medicineGermline mutationFREQUENT CAUSEMANAGEMENTLynchin oireyhtymäneoplasmspaksusuolisyöpäMUTATIONSPoint mutationMLH1METHYLATIONnutritional and metabolic diseasesNONPOLYPOSIS COLORECTAL-CANCERDEFECTSdiagnostiikkalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdigestive system diseases3. Good healthDNA-metylaatioMSH2MSH6030104 developmental biologyLynch syndromeOncologyMSH3syöpägeenitMSH2030220 oncology & carcinogenesisCancer researchDNA mismatch repairsyöpätauditCancers
researchProduct

Genetic variations in the PSMA6 and PSMC6 proteasome genes are associated with multiple sclerosis and response to interferon‑β therapy in Latvians

2021

Several polymorphisms in genes related to the ubiquitin-proteasome system exhibit an association with pathogenesis and prognosis of various human autoimmune diseases. Our previous study reported the association between multiple sclerosis (MS) and the PSMA3-rs2348071 polymorphism in the Latvian population. The current study aimed to evaluate the PSMA6 and PSMC6 genetic variations, their interaction between each other and with the rs2348071, on the susceptibility to MS risk and response to therapy in the Latvian population. PSMA6-rs2277460, -rs1048990 and PSMC6-rs2295826, -rs2295827 were genotyped in the MS case/control study and analysed in terms of genotype-protein correlation network. The …

0301 basic medicineCancer Researcheducation.field_of_studybusiness.industryMultiple sclerosisHaplotypePopulationPSMA6Single-nucleotide polymorphismGeneral MedicineDiseasePSMA3medicine.diseasePSMC603 medical and health sciences030104 developmental biology0302 clinical medicineImmunology and Microbiology (miscellaneous)030220 oncology & carcinogenesisImmunologyMedicinebusinesseducationExperimental and Therapeutic Medicine
researchProduct

Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.

2016

TP53 is a critical tumor suppressor gene that regulates cell cycle progression, apoptosis, cellular senescence and many other properties critical for control of normal cellular growth and death. Due to the pleiotropic effects that TP53 has on gene expression and cellular physiology, mutations at this tumor suppressor gene result in diverse physiological effects. T53 mutations are frequently detected in numerous cancers. The expression of TP53 can be induced by various agents used to treat cancer patients such as chemotherapeutic drugs and ionizing radiation. Radiation will induce Ataxia telangiectasia mutated (ATM) and other kinases that results in the phosphorylation and activation of TP53…

0301 basic medicineCancer Researchendocrine system diseasesMetastasimedicine.disease_causeMetastasisAntineoplastic AgentInvasionNeoplasmsTP53Neoplasm Metastasisbcl-2-Associated X ProteinAza CompoundProto-Oncogene ProteinApoptosis Regulatory ProteinbiologyCell CyclemiRMicroRNACell cycleCell biologyNeoplasm MetastasiGene Expression Regulation NeoplasticNutlin-3 chemosensitivityMdm2Molecular MedicineHumanSignal TransductionCyclin-Dependent Kinase Inhibitor p21Tumor suppressor genemiRsAntineoplastic AgentsCellular senescenceTP53; miRs; MDM2; Nutlin-3 chemosensitivity; Cellular senescence ; Invasion; Metastasis03 medical and health sciencesBcl-2-associated X proteinGeneticMDM2Proto-Oncogene ProteinsmicroRNAGeneticsmedicineHumansNeoplasm InvasivenessneoplasmsMolecular BiologyCell ProliferationNeoplasm InvasiveneAza CompoundsOncomirBridged Bicyclo Compounds HeterocyclicMicroRNAs030104 developmental biologyTumor progressionbiology.proteinNeoplasmTumor Suppressor Protein p53CarcinogenesisApoptosis Regulatory Proteins
researchProduct

Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome

2020

Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by extensive local invasion and systemic spread. In this study, we employed a three-dimensional organoid model of human pancreatic cancer to characterize the molecular alterations critical for invasion. Time-lapse microscopy was used to observe invasion in organoids from 25 surgically resected human PDAC samples in collagen I. Subsequent lentiviral modification and small-molecule inhibitors were used to investigate the molecular programs underlying invasion in PDAC organoids. When cultured in collagen I, PDAC organoids exhibited two distinct, morphologically defined invasive phenotypes, mesenchymal an…

0301 basic medicineCancer Researchendocrine system diseasesPancreatic ductal adenocarcinoma (PDAC)RAC1CDC42AdenocarcinomaBiologyArticle03 medical and health sciences0302 clinical medicineHuman Pancreatic CancerCell MovementPancreatic cancerBiomarkers TumorTumor Cells CulturedmedicineOrganoidHumansNeoplasm InvasivenessCell ProliferationSmad4 ProteinRegulation of gene expressionCell growthMesenchymal stem cellPrognosismedicine.diseasePhenotypedigestive system diseasesGene Expression Regulation NeoplasticOrganoidsPancreatic NeoplasmsSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisembryonic structuresCancer researchCarcinoma Pancreatic DuctalSignal TransductionCancer Research
researchProduct

Impact of glucocorticoids on systemic sirtuin 1 expression and activity in rats with adjuvant-induced arthritis

2020

The class III histone deacetylase sirtuin 1 (SIRT1) plays a pivotal role in numerous biological and physiological functions, including inflammation. An association between SIRT1 and proinflammatory cytokines might exist. In addition to their important role in inflammation associated with rheumatoid arthritis (RA), proinflammatory cytokines mediate the development of systemic effects. Here, we evaluated systemic SIRT1 expression and enzymatic activity, in peripheral blood mononuclear cells (PBMCs) and in liver isolated from rats with adjuvant-induced arthritis (AIA), treated or not with low or high doses of glucocorticoids (GCs). We also measured the production of tumour necrosis factor alph…

0301 basic medicineCancer Researchmedicine.medical_specialtyArthritisInflammationPeripheral blood mononuclear cellProinflammatory cytokine03 medical and health sciences0302 clinical medicineSirtuin 1Internal medicinemedicineAnimalsBeta (finance)Molecular BiologyGlucocorticoidsbiologySirtuin 1Brief ReportDNA Methylationmedicine.diseaseArthritis ExperimentalRats030104 developmental biologyEndocrinology030220 oncology & carcinogenesisRheumatoid arthritisbiology.proteinLeukocytes MononuclearCytokinesTumor necrosis factor alphamedicine.symptom
researchProduct

Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions

2019

Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC. Methods: The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic. Results: We performed an up-to-date critical review taking into account the…

0301 basic medicineCancer Researchmedicine.medical_specialtyAvelumabSkin NeoplasmsPrognosimedicine.medical_treatmentPembrolizumabImmune checkpoint inhibitorCochrane LibraryB7-H1 AntigenSettore MED/13 - EndocrinologiaAvelumab03 medical and health sciencesImmune checkpoint inhibitors0302 clinical medicineMerkel cell carcinomaNeuroendocrine tumoursNeuroendocrine tumourmedicineAnimalsHumansSkin NeoplasmIntensive care medicineMerkel cell carcinomabusiness.industryAnimalAntibodies MonoclonalGeneral MedicineImmunotherapymedicine.diseasePrognosisImmune checkpointBlockadeClinical trialCarcinoma Merkel Cell030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapyTherapyAvelumab; Immune checkpoint inhibitors; Merkel cell carcinoma; Neuroendocrine tumours; Pembrolizumab; TherapybusinessPembrolizumabmedicine.drugHuman
researchProduct